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Some Air for Closure of the
Patent Foramen Ovale*
Bernhard Meier, MD
Bern, Switzerland
The patient is 56 years old. He likes sports, in particular
deep-sea diving. After 2 decompression incidents, he was
worked up by a cardiologist and a patent foramen ovale
(PFO) was found. Incidentally, he mentioned that he has
been increasingly short of breath during physical exercise.
The PFO was closed (Fig. 1) in an outpatient procedure,
and the next day, already, he enjoyed an improved exercise
capacity when jogging. This effect proved to be sustained
and diving has remained uneventful since.
See page 416
It has been known but hardly discussed that a PFO can not
only produce systemic arterial desaturation in elderly people
sitting upright (platypnea-orthodeoxia) but also during exercise
as in the patient described. What has not been known but is
nicely shown by Devendra et al. (1) in this issue of JACC:
Cardiovascular Interventions is that it may do so much more
commonly than previously thought. The investigators found
provoked exercise desaturation in every third patient. This
percentage depends heavily on the indications for PFO clo-
sures and the referral pattern and appears much smaller in our
personal experience. Nonetheless, it adds to the already lengthy
list of possible indications for PFO closure (Table 1).
The focus around PFO closure has always concentrated too
much on patients with prior stroke or transient ischemic
attacks. Notwithstanding, these are the most devastating prob-
lems a PFO can mediate and their issue may be lethal.
However, paradoxical myocardial infarction may also bring
about death and severe disability.
The reticence to implant a device into the middle of the heart
just for preventive reasons is understandable and has re-
cently grown when the results of the yet unpublished
CLOSURE I (A Prospective, Multicenter, Randomized,
Controlled Trial to Evaluate the Safety and Efficacy of the
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ions or the American College of Cardiology.
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ureau of St. Jude Medical.STARFlex Septal Closure System vs. BestMedical Therapy in
Patients with Stroke or Transient Ischemic Attack due to
Presumed Paradoxical Embolism through a Patent Foramen
Ovale) trial failed to prove an advantage of PFO closure over
medical therapy during the first 2 years of follow-up. This may
change should one or both of the controlled randomized trials
on that topic that are expected to be published next meet their
primary endpoints of superiority of PFO closure over medical
treatment. The PC-Trial (Patent Foramen Ovale and Cryp-
togenic Embolism) (NCT00166257) (2) is in the analysis
phase and encompasses roughly 400 patients followed-up for a
minimum of 2 and a maximum of 10 years. The RESPECT
(Randomized Evaluation of Recurrent Stroke Comparing
FO Closure to Established Current Standard of Care Treat-
ent) trial (NCT00465270) is about to be analyzed with a
omparable follow-up duration in about 1,000 patients. Both
rials exclusively used Amplatzer PFO occluders (St. Jude
edical, St. Paul, Minnesota), representing the state-of-the-
rt devices. Meanwhile, the results of a propensity matched
nalysis of about 300 patients with either PFO closure using a
ariety of devices or medical treatment and a median follow-up
f about 10 years supports the procedure by showing even a
ortality benefit when comparing follow-up years with a
losed PFO to those with an open PFO (3).
To place a device into the heart for therapeutic reasons is
much more palatable situation as witnessed in the realm of
nterventional cardiology with coronary stenting and percu-
aneous valve replacement. The migraine indication has lost
team secondary to the negative MIST (Migraine Interven-
ion with STARFlex Technology) trial (4). Yet, PFO
losure does tame migraine symptoms in real life (5).
losing a PFO for platypnea-orthodeoxia is an uncontested
ut rare indication. The opposite is true for closing a PFO
or sleep apnea. Now we do have the newcomer, provoked
xercise desaturation. I suggest that we look for a PFO in
atients complaining about unexplained exertional dyspnea
nd to close it when present, crossing our fingers that the
ymptoms will improve. If they do not, the patient will still
njoy the collateral benefit of not being at risk any longer for
aradoxical embolism be it to the brain, the heart, or
lsewhere. Leaving the PFO open means missing the
hance of symptom improvement and leaving the patient
xposed to rare but serious risks for the rest of his or her life,
ell aware of the fact that these risks increase with age in
arallel to the increase of venous thrombosis (6). Should we
o as far as to test symptomatic PFO carriers for provoked
xercise desaturation as described by Devendra et al. (1)?
robably not, as we usually have a more compelling indi-
ation at hand.
We are indebted to Devendra et al. (1) for opening our
yes to a fact that was there all the time but was just
verlooked. Their original and insightful study on a small
roup of patients with a particular medical situation may
elp to open the door to what some day may become some
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tum primum; SS  septum secundum.
PFO patent foramen ovale.
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421kind of a PFO closure campaign. For the time being, their
study gives PFO closure some direly needed but well-
deserved air.
Reprint requests and correspondence: Dr. Bernhard Meier,
Cardiovascular Department, University Hospital Bern, 3010 Bern,
Switzerland. E-mail: bernhard.meier@insel.ch.
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Figure 1. Right-to-Left Shunt Through a PFO
Right-to-left shunt through a patent foramen ovale (PFO) (dashed arrow) demonstr
and lateral projections. The bottom inset shows the immediate result after closure
Minnesota) and the top inset shows the complete tightness at the 9-month follow-Table 1. Possible Indications for PFO Closure
Secondary prevention
Stroke
Transient ischemic attack
Embolic myocardial infarction
Peripheral embolism
Compression incident
Primary prevention
Aggravating PFO attributes
Atrial-septal aneurysm
Eustachian valve
Chiari network
Deep vein thrombosis
Pulmonary embolism
Embolism-prone surgery
Major orthopedic
Cerebral in sitting position
Planned pregnancy
Therapeutic
Migraine
Platypnea-orthodeoxia
Sleep apnea
Provoked exercise desaturation
Vocational or recreational
Deep-sea diver
Brass musician
Glass blower
Military jet pilot or astronaut
Commercial driver or pilotparadoxical embolism  platypnea-orthodeoxia.
